Effectiveness and Feasibility Associated with Switching to a Second or Third TNF Inhibitor in Patients with Psoriatic Arthritis: A Cohort Study from Southern Sweden.
Research output: Contribution to journal › Article
Because new modes of action for the treatment of psoriatic arthritis (PsA) are emerging, it is important to understand the use of switching to a second or third antitumor necrosis factor (anti-TNF) agent. This study investigated drug survival and treatment response rates of patients with PsA undergoing second- and third-line anti-TNF therapy.
|Research areas and keywords||
Subject classification (UKÄ) – MANDATORY
|Journal||Journal of Rheumatology|
|Publication status||Published - 2016|